Quarterly report pursuant to Section 13 or 15(d)

Note 5 - Fair Value Measurements (Details Textual)

v3.19.3
Note 5 - Fair Value Measurements (Details Textual) - USD ($)
$ in Thousands
3 Months Ended
Sep. 30, 2019
Jun. 30, 2019
Jun. 04, 2019
Oct. 31, 2018
Aug. 01, 2018
Jul. 02, 2018
Business Combination, Liabilities Arising from Contingencies, Amount Recognized     $ 14,600      
Exosome Diagnostics, Inc [Member]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High $ 325,000          
Business Combination, Liabilities Arising from Contingencies, Amount Recognized         $ 3,800  
QT Holdings Corporation [Member]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 51,000          
Business Combination, Liabilities Arising from Contingencies, Amount Recognized           $ 5,300
B-MoGen [Member]            
Business Combination, Contingent Consideration Arrangements, Range of Outcomes, Value, High 38,000   38,000      
Business Combination, Liabilities Arising from Contingencies, Amount Recognized     $ 5,500      
Embedded Derivative Financial Instruments [Member]            
Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, after Tax 0          
Embedded Derivative Financial Instruments [Member] | Cash Flow Hedging [Member]            
Derivative, Notional Amount       $ 380,000    
CCXI [Member]            
Investments, Total $ 18,800 $ 18,800